Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
02/08/201710:54AMBWBristol-Myers Squibb to Take Part in Leerink 6th Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Leerink Annual Global Health Care Conference on Wednesday, February 15, 2017, in New York. Murdo Gordon, executive vice president and chief commercial officer, will answer questions about the company at 3:30 p.m. EST. Investors and the general public are invited... More...>>
02/02/20174:15PMBWBristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothe...
Approval based on CheckMate -275, in which Opdivo demonstrated an objective response rate of 19.6% (95% CI: 15.1-24.9; 53/270 patients)1 Treatment with Opdivo resulted in responses across levels of PD-L1 expression (≥1% vs. <1%)1 Opdivo has now been approved in six tumor types in just over two years1 Bristol-Myers... More...>>
02/02/20179:21AMBWCancer Survivors Need More Efficient Integrated Long-Term Care & Stronger Policies Across Healthcare, Advocacy & the Workplac...
The Economist Intelligence Unit Examines the Growing Worldwide Trend of Cancer Survivorship in a Bristol-Myers Squibb-sponsored research initiative As more patients are living longer with cancer, multi-stakeholder-driven changes are required to improve integrated, or coordinated, care that addresses the range of their... More...>>
02/01/201712:19PMBWBristol-Myers Squibb Announces European Patent Office Decision on Sprycel
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Patent Office (EPO) upheld a decision with regard to European Patent No. 1169038 (the '038 patent), the Composition of Matter patent covering dasatinib, the active ingredient in Sprycel. The EPO upheld a decision that found the patent to be invalid... More...>>
01/26/20171:40PMDJNBristol-Myers Squibb Cuts Guidance on Cancer Drug Problems--Update
By Anne Steele and Jonathan D. Rockoff Bristol-Myers Squibb Co. cut its earnings guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks last year. For 2017, the company now expects adjusted earnings of $2.70 to $2.90 a share, down from its previous guidance of... More...>>
01/26/20177:30AMDJNBristol-Myers Squibb Cuts Guidance on Cancer Drug Problems
By Anne Steele Bristol-Myers Squibb Co. slashed its guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks during the final quarter of the year. For 2017, the company now expects adjusted earnings of $2.70 to $2.90 a share, down from its previous guidance of $2.85... More...>>
01/26/20176:59AMBWBristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results
Increases Fourth Quarter Revenues 22% to $5.2 Billion, 17% for Full Year to $19.4 Billion Posts Fourth Quarter GAAP EPS of $0.53 and Non-GAAP EPS of $0.63 Announces Settlement and License Agreement to Resolve PD-1 Patent Litigation Against Merck Achieves Important Regulatory Milestones for Opdivo Approved in the U.S. for... More...>>
01/20/20174:01PMBWBristol-Myers Squibb & Ono Pharmaceutical Company Enter Settlement & License Agreement with Merck to Resolve PD-1 Antibody Pa...
Merck to pay Bristol-Myers Squibb and Ono royalties on global sales of Keytruda through 2026, and lump-sum payment of $625 million Ends all global patent-infringement litigation against Merck’s sale of Keytruda Recognizes validity of Bristol-Myers Squibb and Ono’s PD-1 antibody patents Bristol-Myers Squibb Company... More...>>
01/19/20176:30PMBWBristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
All First-line Lung Registrational Studies Continue Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of data available at this time. In order to protect... More...>>
01/19/20179:00AMBWOpdivo (nivolumab) Demonstrated Efficacy & Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a...
Opdivo demonstrated a 37% reduction in the risk of death compared to placebo 12-month overall survival rates were 26.6% in Opdivo-treated patients compared to 10.9% in placebo-treated patients Bristol-Myers Squibb Company (NYSE:BMY) announced today the results of ONO-4538-12 demonstrating Opdivo (nivolumab) significantly... More...>>
01/11/20174:17PMDJNTrump Attacks Drugmakers on Pricing
By Joseph Walker Donald Trump attacked the pharmaceutical industry on Wednesday in his first press conference as president-elect, accusing drugmakers of "getting away with murder" and pledging to "save billions of dollars" by changing how the U.S. purchases drugs. "Pharma has a lot of lobbies... More...>>
01/06/20176:59AMBWBristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration
GeneCentric secures equity investment from Bristol-Myers Squibb Bristol-Myers Squibb to explore the use of GeneCentric’s Cancer Subtyping Platform (CSP™) Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of... More...>>
01/05/20176:59AMBWBristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combinatio...
Phase 1b/2 studies to explore a novel Immuno-Oncology combination in hematological and solid tumors with high unmet medical need. Builds off previous clinical collaboration between the companies Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate... More...>>
01/04/20174:05PMGLOBEFive Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Ther...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Bristol-Myers Squibb Company (NYSE:BMY) has exercised its option... More...>>
01/03/20179:18AMBWBristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017, in San Francisco. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 9:30 a.m. PST (12:30 p.m. EST). Investors and the general public are invited to listen... More...>>
12/29/20169:00AMBWBristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2017, in Boston, Massachusetts. Giovanni Caforio, M.D., chief executive officer, will answer questions about the company at 9:30 a.m. EST. Investors and the general public... More...>>
12/21/201610:18AMDJNBristol-Myers Names CEO Giovanni Caforio as New Chairman
By Anne Steele Bristol-Myers Squibb Co. on Wednesday said Chief Executive Giovanni Caforio will add the chairman title this spring, succeeding Lamberto Andreotti, who will retire. The switch, which will be effective at the May 2 shareholder meeting, marks the final exit of one of the leaders who helped transform the pharmaceutical... More...>>
12/21/20168:30AMBWGiovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
Caforio will Succeed Lamberto Andreotti Effective May 2, 2017 Bristol-Myers Squibb Company (NYSE:BMY) today announced that the company’s Board of Directors has appointed Giovanni Caforio, M.D. as chairman of the board, effective May 2, the date of the company’s annual meeting of shareholders. Caforio, who will continue... More...>>
12/21/20166:59AMGLOBEBristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination ...
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology... More...>>
12/21/20166:59AMBWBristol-Myers Squibb & Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination wi...
Study to evaluate potential of CB-839 plus Opdivo to target immune-suppressive cells in the tumor microenvironment Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20170221 05:20:30